纤维蛋白原 FGEN 深 沪
已收盘 01-07 16:00:00 美东时间
9.71
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 9.71
- 总市值 3928.08万
- 52周最高 21.9375
- 市盈率 静 0.21
- 换手率 0.00%
- 52周最低 4.85
- 委 比 0.00%
- 总股本 404.54万
- 历史最高 1713.75
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.50
- 每 手 1
- 风险率 1.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多斩获206GWh储能大单！锂电巨头子公司锁定全球储能龙头五年供货 | 盘后公告精选
锂电巨头锁定全球储能龙头五年供货；金融传媒板块迎来重磅并购；又一国企汽车公司进行重组……今日盘后有哪些值得关注的公告？
09-18 21:00
上海莱士2026年半年报：经营质效持续向好 创新药第二增长曲线渐显
8月24日晚，上海莱士(002252.SZ)发布2026年半年度报告。报告期内，公司实现营业收入32.09亿元，Q2环比增长13%；归母净利润6.61亿元，Q2环比增长9%。
08-24 21:15
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
<p>FibroGen, Inc. rebranded to Kyntra Bio, focusing on oncology and rare disease therapies. The company will trade under the new Nasdaq symbol "KYNB" starting January 8, 2026. Kyntra Bio emphasizes its dedication to impactful treatments, with key assets including FG-3246 (CD46-targeting ADC) and roxadustat. Recent milestones include FDA orphan drug designation for roxadustat in myelodysplastic syndromes and planned clinical trial updates for FG-3...
01-07 12:30
FibroGen Wins FDA Orphan Drug Status for Blood Disorder Treatment Roxadustat
FibroGen, Inc. (NASDAQ:FGEN) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted roxadustat Orphan Drug Designation for the treatment of
2025-12-15 20:10
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
FibroGen, Inc. announced it will attend and present at the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, in New York, NY. Thane Wettig, CEO of FibroGen, will participate in a panel titled "Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts" at 12:15 PM ET. The company's management team will also be available for one-on-one meetings. FibroGen is focused on developing novel therapie...
2025-12-02 21:05
FibroGen Q3 EPS continuing operations $(3.50) Beats $(4.00) Estimate, Sales $1.076M Miss $1.640M Estimate
FibroGen (NASDAQ:FGEN) reported quarterly losses of $(3.50) per share which beat the analyst consensus estimate of $(4.00) by 12.61 percent. This is a 17.65 percent increase over losses of $(4.25) per share from the same
2025-11-11 05:04
FibroGen Receives $6.4 Million Payment from AstraZeneca
FibroGen ( ($FGEN) ) has provided an announcement. On November 6, 2025, FibroGe...
2025-11-07 05:38
FibroGen to Report Third Quarter 2025 Financial Results
FibroGen, Inc. will announce its third quarter 2025 financial results on November 10 after market close. A conference call and webcast presentation will follow at 5:00 PM Eastern Time, featuring FibroGen's management team discussing the financial results and providing a business update. Interested parties can access the live webcast or register for the call via the links provided. FibroGen, a biopharmaceutical company, focuses on developing novel...
2025-11-03 21:02
